The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients

• Published in: BMC cancer Vol. 18; no. 1; p. 1210
• Main Authors: Petrera, Marilena, Paleari, Laura, Clavarezza, Matteo, Puntoni, Matteo, Caviglia, Silvia, Briata, Irene Maria, Oppezzi, Massimo, Mislej, Eva Mihajlovic, Stabuc, Borut, Gnant, Michael, Bachleitner-Hofmann, Thomas, Roth, Wilfried, Scherer, Dominique, Haefeli, Walter-E, Ulrich, Cornelia M, DeCensi, Andrea
• Format: Journal Article
• Language: English
• Published: England BioMed Central 04.12.2018; BMC
• Subjects: 1-Phosphatidylinositol 3-kinase; Adenoma; Antidiabetics; Aspirin; Biomarkers; Biopsy; Cancer therapies; Carcinogenesis; Cell cycle; Chemoprevention; Clinical trials; Colonoscopy; Colorectal cancer; Colorectal carcinoma; Diabetes; Disease prevention; Double-blind studies; Drug dosages; Gastroenterology; Gene expression; Genetic markers; Genomes; Interleukin 6; Kinases; Medical prognosis; Metastases; Metastasis; Metformin; Mortality; Mucosa; Next-generation sequencing; NF-κB protein; p53 Protein; Patients; Proteins; Studies; Study Protocol; Surgery; Tertiary prevention; Tumors; Vascular endothelial growth factor; β-Catenin; Biomarkers; Aspirin; Metformin; Chemoprevention; Tertiary prevention; Colorectal cancer
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-018-5126-7

Epidemiological studies and cardiovascular prevention trials have shown that low-dose aspirin can reduce colorectal cancer (CRC) incidence and mortality, including inhibition of distant metastases. Metformin has also been associated with decreased colon adenoma recurrence in clinical trials and lower CRC incidence and mortality in epidemiological studies in diabetics. While both drugs have been tested as single agents, their combination has not been tested in cancer prevention trials. This is a randomized, placebo-controlled, double-blind, 2 × 2 biomarker trial of aspirin and metformin to test the activity of either agent alone and the potential synergism of their combination on a set of surrogate biomarkers of colorectal carcinogenesis. After surgery, 160 patients with stage I-III CRC are randomly assigned in a four-arm trial to either aspirin (100 mg day), metformin (850 mg bis in die), their combination, or placebo for one year. The primary endpoint biomarker is the change of IHC expression of nuclear factor kappa-B (NFκB) in the unaffected mucosa of proximal and distal colon obtained by multiple biopsies in two paired colonoscopies one year apart. Additional biomarkers will include: 1) the measurement of circulating IL-6, CRP and VEGF; 2) the IHC expression of tissue pS6K, p53, beta-catenin, PI3K; 3) the associations of genetic markers with treatment response as assessed by next generation sequencing of primary tumors; 4) the genomic profile of candidate genes, pathways, and overall genomic patterns in tissue biopsies by genome wide gene expression arrays; and 5) the evaluation of adenoma occurrence at 1 year. A favorable biomarker modulation by aspirin and metformin may provide important clues for a subsequent phase III adjuvant trial aimed at preventing second primary cancer, delaying recurrence and improving prognosis in patients with CRC. EudraCT Number: 2015-004824-77; ClinicalTrial.gov Identifier: NCT03047837 . Registered on February 1, 2017.